Versartis Inc (VSAR)

21.60
0.25 1.14
NASDAQ : Health Care
Prev Close 21.85
Open 21.80
Day Low/High 21.15 / 22.00
52 Wk Low/High 6.17 / 19.76
Volume 883.90K
Avg Volume 328.20K
Exchange NASDAQ
Shares Outstanding 35.63M
Market Cap 698.33M
EPS -3.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Notable Wednesday Option Activity: VSAR, AIMT, WFT

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Versartis Inc , where a total volume of 1,652 contracts has been traded thus far today, a contract volume which is representative of approximately 165,200 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 56.8% of VSAR's average daily trading volume over the past month, of 291,100 shares.

Versartis Reports Second Quarter 2017 Financial Results

Versartis Reports Second Quarter 2017 Financial Results

Confirms Phase 3 Data Expected Late September

Commit To Purchase Versartis At $12.50, Earn 62.3% Annualized Using Options

Investors eyeing a purchase of Versartis Inc shares, but tentative about paying the going market price of $16.45/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the October put at the $12.50 strike, which has a bid at the time of this writing of $2.90.

INVESTOR ALERT: Levi & Korsinsky, LLP Announces An Investigation Concerning Possible Breaches Of Fiduciary Duty By Certain Officers And Directors Of Versartis Inc.

Levi & Korsinsky, LLP announces it has commenced an investigation of Versartis Inc.

Versartis is Now Oversold (VSAR)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Versartis Announces Three Year Somavaratan Data At ENDO 2017 Showing Safety And Efficacy In Line With Historical U.S. Daily RhGH Data In Pediatric GHD

- Mean height velocity during Years 1, 2, and 3 remained consistent and in line with U.S. daily rhGH treatment

Versartis Reports New Data On Long-Acting Somavaratan In Growth Hormone Deficiency At ENDO 2017

- Baseline characteristics of Phase 3 VELOCITY trial population balanced between study arms and comparable to Phase 2

Twitter Is One of Five Stocks Insiders Really Love Right Now

Twitter Is One of Five Stocks Insiders Really Love Right Now

Insiders at these companies have been scooping up shares in their own organizations lately.

Versartis' Pipeline Holds Big Promise

Versartis' Pipeline Holds Big Promise

This small-cap biotech name could have further to run.

Versartis' Pipeline Holds Big Promise

Versartis' Pipeline Holds Big Promise

This small-cap biotech name could have further to run.

Don't Tell Anyone: Insiders Are Buying These Stocks Like Crazy

Don't Tell Anyone: Insiders Are Buying These Stocks Like Crazy

Insiders at Infinity Pharmaceuticals and Och-Ziff Capital Management Group -- among other companies -- have been scooping up shares of their own stock lately.

Commit To Buy Versartis At $10, Earn 46.5% Annualized Using Options

Commit To Buy Versartis At $10, Earn 46.5% Annualized Using Options

Investors eyeing a purchase of Versartis Inc stock, but cautious about paying the going market price of $12.25/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the March 2017 put at the $10 strike, which has a bid at the time of this writing of $1.35.

Versartis Presents Safety, Efficacy And IGF-I Data For Somavaratan In Pediatric Growth Hormone Deficiency At The 2016 Congress Of The GRS & IGF Society

Versartis Presents Safety, Efficacy And IGF-I Data For Somavaratan In Pediatric Growth Hormone Deficiency At The 2016 Congress Of The GRS & IGF Society

Increasing somavaratan dose to the 3.5mg/kg twice-monthly now used in Phase 3 safely improved IGF-I SDS and height velocity from year 1 to year 2